Education
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics, Inc. (US) (CH:SG7)
:SG7
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.79Last Year’s EPS
-1.4Same Quarter Last Year
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: ―
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong growth and milestones achieved for ZURZUVAE, a significant reduction in R&D expenses, and a clear focus on pipeline opportunities. However, there remains uncertainty with ongoing strategic alternatives and continued net losses, albeit reduced.Company Guidance
During Sage Therapeutics' first quarter 2025 financial results conference call, several key metrics were highlighted. The company reported that ZURZUVAE, their oral treatment for postpartum depression (PPD), was shipped to over 3,000 women, marking a 22% increase from the fourth quarter of 2024. ZURZUVAE generated $13.8 million in collaboration revenue, a 21% rise compared to the previous quarter. The company noted that more than 70% of women prescribed ZURZUVAE received it as their first new treatment for PPD, and nearly 80% of prescriptions came from OB/GYNs. Additionally, Sage's R&D expenses decreased by 68% compared to the same period in 2024, reflecting a reorganization aimed at cost savings. The company has $424 million in cash, cash equivalents, and marketable securities as of March 31, 2025, expected to support operations through mid-2027.Strong Start for ZURZUVAE in 2025
ZURZUVAE was shipped to over 3,000 women with PPD in Q1 2025, representing a 22% increase from Q4 2024. Collaboration revenue for ZURZUVAE was $13.8 million, a 21% increase from Q4 2024.
Significant Milestone for ZURZUVAE
Since its launch, ZURZUVAE has been shipped to over 10,000 women with PPD, marking a significant milestone in advancing patient care.
R&D Cost Reduction
R&D expenses were significantly reduced by 68% in Q1 2025 compared to the same period in 2024, and by nearly 40% compared to Q4 2024.
New Pipeline Opportunities
Prioritized clinical pipeline in neuropsychiatry and neurodevelopmental disorders, with potential opportunities for SAGE-319 and NMDA receptor NAM platform.
Financial Stability
Cash runway expected to support operations to mid-2027 with existing cash, equivalents, and marketable securities of $424 million as of March 31, 2025.
---
CH:SG7 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CH:SG7 Earnings-Related Price Changes
No data currently available
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does SAGE Therapeutics, Inc. (US) (CH:SG7) report earnings?
SAGE Therapeutics, Inc. (US) (CH:SG7) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is SAGE Therapeutics, Inc. (US) (CH:SG7) earnings time?
SAGE Therapeutics, Inc. (US) (CH:SG7) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of SAGE Therapeutics, Inc. (US) stock?
The P/E ratio of SAGE Therapeutics is N/A.
What is CH:SG7 EPS forecast?
CH:SG7 EPS forecast for the fiscal quarter 2025 (Q2) is -0.79.
---
